Pharmaceutical

UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer

The UK NICE has declined to recommend Daiichi Sankyo's Enhertu for the treatment of advanced HER2-low breast cancer in adults.

Mar 7, 2024 - 18:00
UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer
The UK NICE has declined to recommend Daiichi Sankyo's Enhertu for the treatment of advanced HER2-low breast cancer in adults.
Read the original article

Tags:

Previous Article

Clinical trials in Africa: Where there is a challenge, there is an opportunity

Next Article

Alumis secures $259m to develop therapies for immune dysfunction

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare...

Sep 20, 2024

Why it won’t be so easy for medicine to displace BMI

Why it won’t be so easy for medicine to displace BMI

Jun 16, 2023

Innovation in immuno-oncology: Leading companies in microbiota restoration therapy

Innovation in immuno-oncology: Leading companies in mic...

May 8, 2023